Riluzole therapy in Huntington's disease (HD)

Movement Disorders

Volumn 14, Issue 2, 1999, Pages 326-330

  Rosas, H Diana ^a   Koroshetz, Walter J ^a   Jenkins, Bruce G ^a   Chen, Y Iris ^a   Hayden, Douglas L ^a   Beal, M Flint ^a   Cudkowicz, Merit E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chorea; Energy metabolism; Huntington's disease; Lactate; Magnetic resonance spectroscopy; Riluzole

Indexed keywords

CREATINE; LACTIC ACID; RILUZOLE;

ADULT; ARTICLE; BASAL GANGLION; CHOREA; CLINICAL ARTICLE; CLINICAL TRIAL; DYSTONIA; FEMALE; HUMAN; HUNTINGTON CHOREA; LACTATE BLOOD LEVEL; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PRIORITY JOURNAL; RATING SCALE;

ADULT; BASAL GANGLIA; CHOREA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; HUNTINGTON DISEASE; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OCCIPITAL LOBE; PILOT PROJECTS; RILUZOLE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0033437155     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q     Document Type: Article

References (28)

1. Greenamyre JT, Shoulson I. Huntington's disease. In: Caine, ed. Neurodegeneration. Philadelphia, PA: WB Saunders, 1994:685-704.
2. Brouillet E, Hamraye P, Ferrante R, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-7109.
3. Palfi S, Ferrante RJ, Brouillet E, et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 1996;16:3019-3025.
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171.
5. Turski L, Turski WA. Towards an understanding of the role of glutamate in neurodegenerative disorders, energy metabolism and neuropathology. Experientia 1993;49:1064-1072.
6. Brouillett E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993;60:356-359.
7. Greene JG, Greenamyre JT. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor melonate. J Neurochem 1995;64:430-436.
8. Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W. Aminooxyacetic acid results in excitoloxic lesions by a novel indirect mechanism. J Neurochem 1991;57:1068-1073.
9. Cooper JK, Schilling G, Peters MF, et al. Truncated N-terminal fragments of huntingtin and expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998;7:783-790.
10. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized IH NMR spectroscopy. Neurology 1993;43:2689-2695.
11. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-738.
12. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1990;31:119-130.
13. Lacomblez L, Bensimon G, Leigh PM, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet 1996; 347:1425-1431.
14. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
15. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:1-4.
16. De Stefano N, Matthews P, Arnold D. Reversible decreases in N-acetylaspartate following acute brain injury. Magn Reson Med 1995;34:721-727.
17. Arnold DL, Matthews PM, De Stefano N. MRI and proton MRS in the evaluation of multiple sclerosis. In: Bachelard H, ed. Magnetic Resonance Spectroscopy and Imaging in Neurochemistry. Nottingham, England: Plenum Press, 1997.
18. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1998;241:462-464.
19. Koroshetz W, Jenkins B, Rosen B, Beal M. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
20. Palfi S, Riche D, Brouillet E, et al. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 1997;146:135-141.
21. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-277.
22. Albin R, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990;322:1293-1298.
23. Bensimon GL, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330: 585-591.
24. Lacomblez L, Bensimon G, Leigh P, Guillett P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347:1425-1431.
25. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-1761.
26. Jenkins B, Rosas HD, Chen YI, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
27. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 1995;201:92-96.
28. Guyot MC, Palfi S, Stutzman JM, Maziere M, Hantraye P, Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 1997;81:141-149.